(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
X4 Pharmaceuticals's revenue in 2024 is $0.On average, 6 Wall Street analysts forecast XFOR's revenue for 2024 to be $4,157,299,769, with the lowest XFOR revenue forecast at $419,844,453, and the highest XFOR revenue forecast at $19,405,210,595. On average, 6 Wall Street analysts forecast XFOR's revenue for 2025 to be $9,266,470,880, with the lowest XFOR revenue forecast at $1,566,859,497, and the highest XFOR revenue forecast at $27,390,652,081.
In 2026, XFOR is forecast to generate $19,768,963,828 in revenue, with the lowest revenue forecast at $3,761,806,294 and the highest revenue forecast at $49,306,532,502.